中国实验血液学杂志最新文献

{"title":"[Research Progress of Metabolomics in Hematological Malignancies --Review].","authors":"Han-Ke Wang, Jun Guan, Lin Zhou","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.047","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.047","url":null,"abstract":"<p><p>In recent years, as a new omics field, metabolomics has been proved to be of great value in the study of the mechanism of occurrence and progression, the screening of new biomarkers and the development of novel therapeutic strategies in many diseases including tumors. In this review, we briefly summarized the research methods and techniques of metabolomics, and focused on the latest research progress of metabolomics in the pathogenesis of hematological malignancies represented by leukemia, lymphoma and multiple myeloma, screening of biomarkers for diagnosis and prognosis, and development of new therapeutic strategies. This article proposes the limitations of metabolomics and future research strategies, and provides a new exploration direction for accurate diagnosis and treatment as well as prognosis evaluation of hematological malignancies.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"616-620"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Applications of Circulating Tumor DNA in Response Evaluation and Relapse Monitoring of Primary Mediastinal Large B-Cell Lymphoma].","authors":"Lu Pan, Xin-Miao Jiang, Yan Teng, Ning Wang, Ling Huang, Han-Guo Guo, Si-Chu Liu, Xiao-Juan Wei, Fei-Li Chen, Zhan-Li Liang, Wen-Yu Li","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.014","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.014","url":null,"abstract":"<p><strong>Objective: </strong>To explore the clinical significance of circulating tumor DNA (ctDNA) in response evaluation and relapse monitoring for patients with primary mediastinal large B-cell lymphoma (PMBCL).</p><p><strong>Methods: </strong>The clinical characteristics, efficacy and survival of 38 PMBCL patients in our hospital from January 2010 to April 2020 were retrospectively analyzed. The ctDNA monitoring was conducted by targeted next-generation sequencing (NGS).</p><p><strong>Results: </strong>Among the 38 patients, 26 cases were female, and 32 cases were diagnosed with Ann Arbor stage I-II. The 5-year overall survival (OS) rate and progression-free survival (PFS) rate were 74.7% and 61.7%, respectively. Males and those with high aaIPI scores (3 points) had a relatively poor prognosis. The NGS results of 23 patients showed that <i>STAT6</i> (65.2%), <i>SOCS1</i> (56.5%), and <i>TNFAIP3</i> (56.5%) were the most common mutated genes. Patients with stable disease (SD)/progressive disease (PD) exhibited enrichment in cell cycle, FoxO, and TNF signaling pathways. A total of 29 patients underwent end-of-treatment PET/CT (EOT PET/CT), and 16 of them received ctDNA monitoring with 12 negative. Among 6 patients with EOT PET/CT positive (Deauville 4), 4 underwent ctDNA monitoring, and 3 of them were negative, being still in continuous remission without any subsequent anti-tumor therapy.</p><p><strong>Conclusion: </strong>CtDNA may be combined with PET/CT to assess efficacy, monitor relapse, and guide treatment of PMBCL.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"407-415"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144037517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Study on Reentry Strategy and Results of Blood Donors with Single Reagent Reactivity in Wuhan Area].","authors":"Ting-Ting Xu, Qin Yu, Song-Qing Ke, Yan Cai, Song-Li Xie, Jing Xiong, Lei Zhao","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.033","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.033","url":null,"abstract":"<p><strong>Objective: </strong>To study the results, re-donation situation and characteristics of single-reagent reactive blood donors who were put into the reentry strategy in Wuhan area, explore the rationality and effectiveness of the current reentry strategy, and provide data support for the improvement of the reentry process of blood donors.</p><p><strong>Methods: </strong>From January 2020 to December 2023, blood donors who conform the reentry criteria and voluntarily applied for returning to Wuhan Blood Center were tested and the results were analyzed. According to the reentry strategy, serological testing and nucleic acid testing were carried out in parallel, serological testing was performed by ELISA with reagents from two different manufacturers, and the primary reactive samples were tested by double-well retest, and HBV/HCV/HIV nucleic acid detection was performed by RT-PCR with an individual donor test mode. Supplementary HBcAb testing was applied for HBV single reagent reactivity by chemiluminescence method. Supplementary TP-WB testing was applied for returning blood donors with repeated TP single reagent reactivity. If returning blood donors with HIV single reagent reactivity were repeated single reagent reactivity, the samples were sent to local CDC for confirmatory test.</p><p><strong>Results: </strong>7 098 blood donors were qualified for reentry, 716 donors voluntarily applied for reentry, 436 donors successfully reentry, 251 donors entered the next round, 29 donors could not reentry. The reentry rates for the past four years were 66.67%（42/63）, 54.73%（81/148）, 60.71%（136/224） and 62.99%（177/281）, respectively. Up to December 31, 2023, 275 donors donated blood again, and the donation rates for past four years were 76.19%（32/42）, 72.84%（59/81）, 61.76%（84/136） and 56.50%（100/177）, respectively. After donating blood, 31 donors were disqualified again by blood screening and subjected to permanent deferral. The results of returning to the team had statistical differences in reentry items, educational level, age, and marriage（<i>P</i> < 0.05）.</p><p><strong>Conclusion: </strong>The current reentry strategy adopted by the blood donation and supply institution can effectively retain part of blood donors, reduce the negative emotions of blood donors and increase blood resources.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"530-537"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The Significance of Bone Marrow Plasma Cell Percentage and Immature Plasma Cells in the Prognosis of Newly Diagnosed Multiple Myeloma Patients].","authors":"Yuan-Yuan Zhang, Qi-Ke Zhang, Xiao-Fang Wei, You-Fan Feng, Yuan Fu, Fei Liu, Qiao-Lin Chen, Yang-Yang Zhao, Xiu-Juan Huang, Yang Chen","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.023","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.023","url":null,"abstract":"<p><strong>Objective: </strong>To explore the significance of the plasma cell percentage and immature plasma cells in the prognosis of patients with multiple myeloma (MM).</p><p><strong>Methods: </strong>The clinical data of 126 newly diagnosed MM patients in Gansu Provincial Hospital from June 2017 to November 2022 were retrospectively analyzed. The enrolled patients were divided into a higher plasma cell percentage group (group A) and a lower plasma cell percentage group (group B) according to the median plasma cell percentage (33.5%). The clinicopathological data of the two groups were compared, and the effect of plasma cell percentage on the prognosis of MM patients was analyzed using survival curves. On this basis, group A and group B were divided into subgroups with immature plasma cells (A1 group, B1 group) and subgroups without immature plasma cells (A2 group, B2 group), respectively, then the survival curves were used to analyze the effect of immature plasma cells on the prognosis of MM patients.</p><p><strong>Results: </strong>Among the 126 patients with MM, the proportions of patients with ISS stage III, elevated β₂-microglobulin(β₂-MG) level, and immature plasma cells in Group A were significantly higher compared those in Group B ( <i>P</i> =0.015, <i>P</i> =0.028, <i>P</i> =0.010). The median overall survival(OS) and progression-free survival(PFS) of group A were 32 months and 10 months, respectively. The median OS of group B was not reached, and the median PFS was 32 months. The 3-year OS rates of patients in group A and group B were 46.7% and 62.2%, respectively ( <i>P</i> =0.021), and the 3-year PFS were 29.2% and 42.5%, respectively ( <i>P</i> =0.033). There were no significant differences in OS and PFS between group A1 and group A2, or between group B1 and group B2 ( <i>P</i> >0.05). Multivariate COX survival analysis showed that the plasma cell percentage ≥33.5%（<i>HR</i>=1.253, 95%<i>CI</i> : 0.580-2.889, <i>P</i> =0.018）, age ≥65 years (<i>HR</i>=2.206, 95%<i>CI</i> : 1.170-3.510, <i>P</i> =0.012), lactate dehydrogenase(LDH) ≥250 U/L (<i>HR</i>=1.180, 95%<i>CI</i> : 0.621-2.398, <i>P</i> =0.048) and β₂-MG ≥3.5 mg/L (<i>HR</i>=1.507, 95%<i>CI</i> : 0.823-3.657, <i>P</i> =0.036) were independent risk factors affecting OS in MM patients.</p><p><strong>Conclusion: </strong>MM patients with a higher plasma cell percentage (≥33.5%) at the initial diagnosis have a later disease stage, poorer OS and PFS, compared to the patients with a lower percentage(<33.5%) of plasma cells. The presence or absence of immature plasma cells has no significant impact on the survival of MM patients.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"469-474"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Protective Effects of Low-Dose Irradiated Autologous Peripheral Blood Reinfusion on Radiation -Induced Leukopenia in Rats: An Experimental Study].","authors":"Gao-Feng He, Shuang Ge, Li-Ping Sun, De-Qing Wang, Yang Yu","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.030","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.030","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effects of low-dose irradiated autologous peripheral blood reinfusion (LDIAPBR) on a rat model of radiation-induced leukopenia.</p><p><strong>Methods: </strong>The rats were randomly divided into four groups. In the LDIAPBR group, LDIAPBR was performed 1 day before modeling (10% of the total circulating blood volume was withdrawn, irradiated with 100 mGy ex vivo, and completely reinfused). Meanwhile, the normal group and model group only underwent blood withdrawal and reinfusion of the same proportion without blood irradiation. Except for the normal group, all groups were subjected to 1 Gy X-ray whole-body irradiation to establish a radiation-induced leukopenia rat model. The positive drug group received subcutaneous injection of rhG-CSF after modeling. It was monitored that the general condition of the rats, peripheral blood cell counts, immune organ indices, bone marrow nucleated cell counts and viability, and the pathological analysis of bone marrow sections was conducted.</p><p><strong>Results: </strong>The LDIAPBR group exhibited significant improvements in overall condition compared to the model group. Notably, compared with the model group, peripheral blood leukocyte and lymphocyte counts were markedly higher in the LDIAPBR group. Furthermore, there was a significant increase in both the number and viability of nucleated cells in the bone marrow. Pathological examination of bone marrow sections revealed increased nucleated cell density and reduced cavity area in the LDIAPBR group.</p><p><strong>Conclusion: </strong>LDIAPBR can effectively improve hematological parameters and bone marrow hematopoietic function in a rat model of radiation-induced leukopenia, providing a new approach for the prevention and treatment of radiation-related injuries.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"511-519"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144019100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Efficacy and Survival Analysis of Chidamide Combined with DICE Regimen in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma].","authors":"Li-Li Wu, Li Shi, Wei-Jing Li, Wei Liu, Yun Feng, Shao-Ning Yin, Cui-Ying He, Li-Hong Liu","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.010","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.010","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the efficacy and safety of chidamide combined with DICE regimen (cisplatin+ ifosfamide + etoposide + dexamethasone) for relapsed/refractory diffuse large B-cell lymphome(R/R DLBCL).</p><p><strong>Methods: </strong>The clinical data of 31 R/R DLBCL patients treated by chidamide combined with DICE regimen in the Hematology Department of the Fourth Hospital of Hebei Medical University from October 2016 to October 2020 were retrospectively analyzed. The clinical efficacy and adverse events were observed.</p><p><strong>Results: </strong>Among the 31 patients, 20 were male and 11 were female. The median age of the patients was 55 (range: 27-71) years old, 21 cases were < 60 years old, 10 cases were ≥60 years old. 26 cases were refractory and 5 cases were relapsed. There were 13 cases of germinal center B-cell like (GCB), 17 cases of non-GCB, and 1 case had missing Hans type. There were 17 cases of double-expression lymphoma (DEL) and 14 cases of non-DEL. The complete response rate of patients was 38.7%(12/31), the overall response rate was 67.7%(21/31). The median progression-free survival time and the median overall survival time were 9.8(95%<i>CI</i> : 4.048-15.552) months, 13.9(95%<i>CI</i> : 9.294-18.506) months, respectively. Multipvariate analysis showed that GCB and DEL reduced the risk of disease recurrence in R/R DLBCL patients. The main grade 3/4 hematological adverse events in this study were thrombocytopenia, agranulocytosis, anemia and leukopenia.</p><p><strong>Conclusion: </strong>The chidamide combined with DICE regimen is effective in the treatment of R/R DLBCL, and hematological adverse events should be closely monitored.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"373-378"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Characteristics and Prognosis of Primary Pulmonary Lymphoma].","authors":"You-Fan Feng, Yuan-Yuan Zhang, Xiao Fang Wei, Qi-Ke Zhang, Li Zhao, Xiao-Qin Liang, Yuan Fu, Fei Liu, Yang-Yang Zhao, Xiu-Juan Huang, Qing-Fen Li","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.012","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.012","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical characteristics and prognosis of primary pulmonary lymphoma (PPL).</p><p><strong>Methods: </strong>The clinical data of 17 patients with PPL admitted to Gansu Provincial Hospital from January 2013 to June 2023 were collected, and their clinical characteristics and prognosis were retrospectively analyzed and summarized.</p><p><strong>Results: </strong>The median age of the 17 patients was 56 (29-73) years old. There were 8 males and 9 females. According to Ann Arbor staging system, there were 9 patients with stage I-II and 8 patients with stage III-IV. There were 14 patients with IPI score of 0-2 and 3 patients with IPI score of 3-4. All 17 patients had symptoms at the initial diagnosis, most of the first symptoms were cough, and 6 patients had B symptoms.Among the 17 patients, there were 8 cases of diffuse large B-cell lymphoma (DLBCL), 5 cases of mucosa-associated lymphoid tissue (MALT) lymphoma, 1 case of gray zone lymphoma (GZL), and 3 cases of Hodgkin's lymphoma (HL). 15 patients received chemotherapy, of which 3 cases received autologous hematopoietic stem cell transplantation(ASCT) and 3 cases received radiotherapy; 2 patients did not receive treatment. The median number of chemotherapy courses was 6(2-8). The short-term efficacy was evaluated, 12 patients achieved complete remission (CR) and 3 patients achieved partial remission (PR). The age, pathological subtype, sex, Ann Arbor stage, β₂-microglobulin(β₂-MG) level, lactate dehydrogenase(LDH) level were not correlated with CR rate (<i>P</i> >0.05), while IPI score was correlated with recent CR rate (<i>P</i> < 0.05 ). The median follow-up time was 31(2-102) months. One of the 12 CR patients died of COVID-19, and the rest survived. Among the 3 patients who did not reach CR, 1 died after disease progression, while the other 2 survived. One of the 2 untreated patients died one year after diagnosis. Both the median progression-free survival (PFS) time and overall survival (OS) time of the 17 patients were both 31 (2-102) months.</p><p><strong>Conclusion: </strong>The incidence of PPL is low, and the disease has no specific clinical manifestations, which is easily missed and misdiagnosed. The pathological subtypes are mainly MALT lymphoma and DLBCL, and the treatment is mainly combined chemotherapy. The IPI score is related to the treatment efficacy.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"387-392"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Family Studies of a New Allele of the B_el subtype (c.803G>T, p.Gly268Val)].","authors":"Xiao-Li Ma, Wen-An Dong, He-Cai Yang, Ming-Lu Geng, Li-Ping Wang, Yang Yu","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.029","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.029","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the B_el subtype gene mutation and its genetic mechanism in a family line.</p><p><strong>Methods: </strong>ABO blood groups were identified by serologic tests. <i>ABO</i> genotyping was performed by polymerase chain reaction with sequence-specific primer (PCR-SSP). Sanger sequencing was performed on exons 1-7 of the <i>ABO</i> gene, the flanking intronic region, and exon 7 of the single strand of the gene confirmed the mutation site location. Missense3D software was used to predict the protein structure alteration caused by this mutation.</p><p><strong>Results: </strong>Conventional serologic tests failed to detect erythrocyte B antigen in the proband and her three family members, and only trace amounts of B antigen expression could be detected by the absorption-dispersal test. DNA analysis showed that, on the basis of the normal <i>ABO</i> gene, there was a G>T substitution in the position of exon 7, position 803, which resulted in the change of amino acid 268 from Gly to Val. Further single-stranded sequencing analysis showed that the mutation site was located in the <i>B</i> gene.</p><p><strong>Conclusion: </strong>In this family line, the proband, her father, her son, and her daughter all have reduced <i>B</i> type glycosyltransferase activity due to the new point mutation (c.803G>T) in exon 7 of the <i>B</i> gene, and the B antigen can only be detected by the absorption-dispersal method, and the point mutation can be stably inherited by offspring.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"504-510"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144046519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The Expression and Clinical Significance of <i>TCP1</i> in Newly Diagnosed Acute Myeloid Leukemia Patients].","authors":"Jia-Jia Li, Yan-Ping Wu, Lin Liu, Meng-Meng Zhang, Meng Wang, Ping-Ping Zhang, Feng Zhang","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.005","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.005","url":null,"abstract":"<p><strong>Objective: </strong>To detect the expression level of T-complex polypeptide 1 (TCP1) in the bone marrow of newly diagnosed acute myeloid leukemia (AML) patients, and explore its correlation with clinical characteristics and prognosis.</p><p><strong>Methods: </strong>The bone marrow samples from 80 newly diagnosed AML patients and 30 iron deficiency anemia (IDA) patients were collected, and real time fluorescence quantitative PCR was used to detect the expression level of <i>TCP1</i> . The clinical data of AML patients were collected, and the correlation of <i>TCP1</i> expression with clinical characteristics and prognosis of patients were analyzed. The impact of <i>TCP1</i> on overall survival (OS) of AML patients was identified by using Kaplan-Meier curve analysis. Cox regression analysis was used to identify the factors affecting prognosis of AML patients.</p><p><strong>Results: </strong>Compared with IDA patients, the expression of <i>TCP1</i> was significantly increased in AML patients (<i>P</i> < 0.01). The high expression group of <i>TCP1</i> showed a higher proportion of patients with ≥60 years and non-remission after treatment, more accompanied by <i>TET2</i> mutation and poor prognosis but shorter OS compared to the low expression group (all <i>P</i> < 0.05). The results of multivariate Cox regression analysis showed that age, chromosomal abnormalities, therapeutic efficacy and <i>TCP1</i> expression were independent risk factors affecting prognosis of AML patients (all <i>P</i> < 0.05).</p><p><strong>Conclusion: </strong><i>TCP1</i> is significantly upregulated in AML patients, and its expression is associated with partial clinical features and poor prognosis. It can serve as a prognostic indicator and potential therapeutic target for AML patients.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"339-343"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Efficacy Prediction of Platelet Count Trajectories after Induction Therapy with Venetoclax Combined with Azacitidine in Newly Diagnosed AML Patients].","authors":"Qian-Ying Ma, Xiao-Rui Jing, Han-Chun Wang, Hui-Rong Wu, Juan Cheng","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.004","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.004","url":null,"abstract":"<p><strong>Objective: </strong>To investigate platelet count trajectories after induction therapy with venetoclax combined with azacitidine (VA regimen) in newly diagnosed AML patients and further analyze its clinical significance.</p><p><strong>Methods: </strong>Clinical date of 50 newly diagnosed AML patients who received VA treatment from March 2020 to July 2023 in Department of Hematology of the First Hospital of Lanzhou University were retrospectively collected. The platelet trajectories after induction chemotherapy were constructed by using group-based trajectory modeling. To study the association between diverse trajectories of platelet counts and compound complete remission (cCR) rate, overall response rate (ORR), minimal residual disease (MRD) negative rate and overall survival (OS) rate. The Cox proportional hazard model was used to evaluate the relationship between platelet trajectory and OS. The logistic regression was used to analyze the influence of individual characteristics on platelet trajectory.</p><p><strong>Results: </strong>Two platelet trajectories were identified based on the model, including platelet slowly increased group (<i>n</i>=31, 62.0%) and platelet rapidly increased group (<i>n</i>=19, 38.0%). There were statistically significant differences in cCR rate, ORR and OS rate between platelet slowly increased group and platelet rapidly increased group (all <i>P</i> < 0.05). The Cox regression analysis showed that platelet rapidly increased group was associated with a decreased risk of mortality compared with platelet slowly increased group (<i>HR</i>=0.153, 95%<i>CI</i> : 0.045-0.527, <i>P</i> =0.003). Logistic regression analysis showed that <i>IDH1</i>/2 mutation (<i>OR</i> =3.908, 95%<i>CI</i> : 1.023-14.923, <i>P</i> =0.046) and platelet transfusion (<i>OR</i> =0.771, 95%<i>CI</i> : 0.620-0.959, <i>P</i> =0.020) were independent influencing factors of platelet trajectory.</p><p><strong>Conclusion: </strong>The dynamic trajectory of platelet counts in newly diagnosed AML patients who received VA treatment can serve as a significant indicator to observe the efficacy and prognosis. The platelet rapidly increased is an independent protective factor for good prognosis. The<i>IDH1</i> /2 mutation and platelet transfusion are independent influencing factors of platelet trajectory.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"331-338"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144040220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}